Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Erytech Pharma (NASDAQ: ERYP).

Full DD Report for ERYP

You must become a subscriber to view this report.


Recent News from (NASDAQ: ERYP)

ERYTECH to Host Second Quarter 2018 Conference Call and Business Update
LYON, France, Sept. 06, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host a second qua...
Source: Thomson Reuters ONE
Date: September, 06 2018 01:30
ERYTECH Pharma Reports Voting Results from Annual General Meeting Held on June 28, 2018
LYON, France and CAMBRIDGE, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP) announced that its 2018 Annual General Meeting was held in Lyon on Thursday, June 28, 2018. At the meeting, all resolutions for which management recommended a vote in favor, ...
Source: GlobeNewswire
Date: July, 17 2018 16:30
Rubius Therapeutics Proposes Terms For $200 Million IPO
Quick Take Rubius Therapeutics ( RUBY ) intends to raise $200 million from the sale of its common stock in a U.S. IPO, according to an SEC filing . The firm is a very early stage biopharma developing a diverse pipeline of treatments using red blood cells as the primary delivery mechanis...
Source: SeekingAlpha
Date: July, 09 2018 17:23
Erytech Pharma (ERYP) Confirms Strategic Focus Of Eryaspase On Solid Tumors And Ceases Development In Acute Lymphoblastic Leukemia - Slideshow
The following slide deck was published by Erytech Pharma S.A. ADS in conjunction with this Read more ...
Source: SeekingAlpha
Date: June, 26 2018 14:00
3 Things In Biotech, June 26: One Piece Of Good News Offset By A Cascade Of Bad?
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Roche scores a momentous win in small cell lung cancer Company: Roche (RHHBF) Therapy...
Source: SeekingAlpha
Date: June, 26 2018 08:00
Erytech Pharma -29% after stopping development of key drug
Erytech Pharma ( ERYP -29.2% ) plunges to a record low after saying it will stop its development program for its eryaspase product candidate in acute lymphoblastic leukemia. More news on: Erytech Pharma S.A. ADS, Erytech Pharma ADR, Healthcare stocks news, Stocks on the move, Read ...
Source: SeekingAlpha
Date: June, 25 2018 15:58
ERYTECH Confirms Strategic Focus of Eryaspase on Solid Tumors and Ceases Development in Acute Lymphoblastic Leukemia
Focuses development efforts on solid tumor indications Confirms planned launch of company-sponsored randomized Phase 2 trial in first-line pancreatic cancer, in addition to ongoing launch of Phase 3 trial in second-line pancreatic cancer. Expands eryaspase production capacity in th...
Source: GlobeNewswire
Date: June, 24 2018 16:51
ERYTECH to Present at JMP Securities Life Science Conference
LYON, France, June 20, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris:ERYP) (Nasdaq:ERYP) , a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Chief Executive Officer...
Source: GlobeNewswire
Date: June, 20 2018 01:30
ERYTECH to Present Preclinical and Clinical Data on Use of Eryaspase in ALL and AML at EHA 2018
LYON, France, June 15, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP) , a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will present preclinical...
Source: GlobeNewswire
Date: June, 15 2018 01:30
Erytech Pharma S.A. : General Meeting to be held on June 28, 2018 and Availability of Related Materials
LYON, France, June  07, 2018  (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris:ERYP) (Nasdaq:ERYP) , a clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases based on its proprietary ERYCAPS platform, encapsulati...
Source: Thomson Reuters ONE
Date: June, 07 2018 01:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0810.23539.6410.3919.64890
2018-05-1720.0020.0020.0020.00575

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-124,6678,32756.0466Short
2018-12-112,0002,30086.9565Short
2018-12-1033100.0000Short
2018-12-0734340.6912Cover
2018-11-305001,15043.4783Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ERYP.


About Erytech Pharma (NASDAQ: ERYP)

Logo for Erytech Pharma (NASDAQ: ERYP)

Not available

 

Contact Information

     

     

    Current Share Structure

       



      Daily Technical Chart for (NASDAQ: ERYP)

      Daily Technical Chart for (NASDAQ: ERYP)


      Stay tuned for daily updates and more on (NASDAQ: ERYP)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: ERYP)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ERYP is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ERYP and does not buy, sell, or trade any shares of ERYP. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/